Minoxidil baldness: Drug Database | Medication Decision Support
Minoxidil and its use in hair disorders: a review
1. Campese VM. Minoxidil: a review of its pharmacological properties and therapeutic use. Drugs. 1981;22(4):257–278. doi: 10.2165/00003495-198122040-00001 [PubMed] [CrossRef] [Google Scholar]
2. Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(2):130–136. [PubMed] [Google Scholar]
3. Tata S, Weiner N, Flynn G. Relative influence of ethanol and propylene glycol cosolvents on deposition of minoxidil into the skin. J Pharm Sci. 1994;83(10):1508–1510. doi: 10.1002/jps.2600831026 [PubMed] [CrossRef] [Google Scholar]
4. Gogtay JA, Panda M. Minoxidil topical foam: a new kid on the block. Int J Trichology. 2009;1(2):142. doi: 10.4103/0974-7753.58560 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
5. Purnak T, Senel E, Sahin C. Liquid formulation of minoxidil versus its foam formulation. Indian J Dermatol. 2011;56(4):462. doi: 10.4103/0019-5154.84714 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Shorter K, Farjo NP, Picksley SM, Randall VA. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. Faseb J. 2008;22(6):1725–1736. doi: 10.1096/fj.07-099424 [PubMed] [CrossRef] [Google Scholar]
7. Xu D, Wang L, Dai W, Lu L. A requirement for K+-channel activity in growth factor-mediated extracellular signal-regulated kinase activation in human myeloblastic leukemia ML-1 cells. Blood. 1999;94(1):139–145. [PubMed] [Google Scholar]
8. Malhi H, Irani AN, Rajvanshi P, et al. KATP channels regulate mitogenically induced proliferation in primary rat hepatocytes and human liver cell lines. Implications for liver growth control and potential therapeutic targeting. J Biol Chem. 2000;275(34):26050–26057. [PubMed] [Google Scholar]
9. Buhl AE, Waldon DJ, Kawabe TT, Holland JM. Minoxidil stimulates mouse vibrissae follicles in organ culture. J Invest Dermatol. 1989;92(3):315–320. [PubMed] [Google Scholar]
10. Anderson RJ, Kudlacek PE, Clemens DL. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact. 1998;109(1–3):53–67. [PubMed] [Google Scholar]
11. Goren A, Sharma A, Dhurat R, et al. Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. Dermatol Ther. 2018;31(6):e12741. doi: 10.1111/dth.12741 [PubMed] [CrossRef] [Google Scholar]
12. Lowenthal DT, Affrime MB. Pharmacology and pharmacokinetics of minoxidil. J Cardiovasc Pharmacol. 1980;2 Suppl 2:S93–S106. doi: 10.1097/00005344-198000022-00002 [PubMed] [CrossRef] [Google Scholar]
13. Mori O, Uno H. The effect of topical minoxidil on hair follicular cycles of rats. J Dermatol. 1990;17(5):276–281. [PubMed] [Google Scholar]
14. Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol. 1999;41(5 Pt 1):717–721. doi: 10.1016/s0190-9622(99)70006-x [PubMed] [CrossRef] [Google Scholar]
15. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–385. doi: 10.1067/mjd.2002.124088 [PubMed] [CrossRef] [Google Scholar]
16. Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186–194. doi: 10.1111/j.1365-2133.2004.05785.x [PubMed] [CrossRef] [Google Scholar]
17. Abell E. Histologic response to topically applied minoxidil in male-pattern alopecia. Clin Dermatol. 1988;6(4):191–194. [PubMed] [Google Scholar]
18. Headington IT, Novak E. Clinical and histologic studies of male pattern baldness treated with topical minoxidil. Curr Ther Res 1984;36:1098–1106. [Google Scholar]
19. Sakita S, Kagoura M, Toyoda M, Morohashi M. The induction by topical minoxidil of increased fenestration in the perifollicular capillary wall. Br J Dermatol. 1999;140(2):294–296. doi: 10.1046/j.1365-2133.1999.02666.x [PubMed] [CrossRef] [Google Scholar]
20. Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol. 1998;138(3):407–411. doi: 10.1046/j.1365-2133.1998.02115.x [PubMed] [CrossRef] [Google Scholar]
21. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107(4):409–417. doi: 10.1172/JCI11317 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
22. Yum S, Jeong S, Kim D, et al. Minoxidil Induction of VEGF is mediated by inhibition of HIF-Prolyl hydroxylase. Int J Mol Sci. 2017;19(1). doi: 10.3390/ijms19010053 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
23. Michelet JF, Commo S, Billoni N, Mahe YF, Bernard BA. Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol. 1997;108(2):205–209. doi: 10.1111/1523-1747.ep12334249 [PubMed] [CrossRef] [Google Scholar]
24. Kvedar JC, Baden HP, Levine L. Selective inhibition by minoxidil of prostacyclin production by cells in culture. Biochem Pharmacol. 1988;37(5):867–874. doi: 10.1016/0006-2952(88)90174-8 [PubMed] [CrossRef] [Google Scholar]
25. Shin H, Kwack MH, Shin SH, et al. Identification of transcriptional targets of Wnt/beta-catenin signaling in dermal papilla cells of human scalp hair follicles: EP2 is a novel transcriptional target of Wnt3a. J Dermatol Sci. 2010;58(2):91–96. doi: 10.1016/j.jdermsci.2010.02.011 [PubMed] [CrossRef] [Google Scholar]
26. Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32(12):2257–2263. doi: 10.1111/jdv.15171 [PubMed] [CrossRef] [Google Scholar]
27. Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. Am J Clin Dermatol. 2019;20(1):147–153. doi: 10.1007/s40257-018-0387-0 [PubMed] [CrossRef] [Google Scholar]
28. Rojhirunsakool S, Suchonwanit P. Parietal scalp is another affected area in female pattern hair loss: an analysis of hair density and hair diameter. Clin Cosmet Investig Dermatol. 2018;11:7–12. doi: 10.2147/CCID.S153768 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
29. Cotsarelis G, Millar SE. Towards a molecular understanding of hair loss and its treatment. Trends Mol Med. 2001;7(7):293–301. [PubMed] [Google Scholar]
30. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136–141.e135. doi: 10.1016/j.jaad.2017.02.054 [PubMed] [CrossRef] [Google Scholar]
31. Olsen EA, Weiner MS, Amara IA, DeLong ER. Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol. 1990;22(4):643–646. doi: 10.1016/0190-9622(90)70089-z [PubMed] [CrossRef] [Google Scholar]
32. Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767–774. doi: 10.1016/j.jaad.2007.04.012 [PubMed] [CrossRef] [Google Scholar]
33. Berger RS, Fu JL, Smiles KA, et al. The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol. 2003;149(2):354–362. doi: 10.1046/j.1365-2133.2003.05435.x [PubMed] [CrossRef] [Google Scholar]
34. Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541–553. doi: 10.1016/j.jaad.2003.06.014 [PubMed] [CrossRef] [Google Scholar]
35. Tsuboi R, Tanaka T, Nishikawa T, et al. A randomized, placebo-controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. Eur J Dermatol. 2007;17(1):37–44. doi: 10.1684/ejd.2007.0187 [PubMed] [CrossRef] [Google Scholar]
36. Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011;65(6):1126–1134.e1122. doi: 10. 1016/j.jaad.2010.09.724 [PubMed] [CrossRef] [Google Scholar]
37. Blume-Peytavi U, Shapiro J, Messenger AG, et al. Efficacy and safety of once-daily minoxidil foam 5% versus twice-daily minoxidil solution 2% in female pattern hair loss: a Phase III, randomized, investigator-blinded study. J Drugs Dermatol. 2016;15(7):883–889. [PubMed] [Google Scholar]
38. Kelly Y, Blanco A, Tosti A. Androgenetic alopecia: an update of treatment options. Drugs. 2016;76(14):1349–1364. doi: 10.1007/s40265-016-0629-5 [PubMed] [CrossRef] [Google Scholar]
39. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776–789. doi: 10.1542/peds.108.3.776 [PubMed] [CrossRef] [Google Scholar]
40. Roberts J, Desai N, McCoy J, Goren A. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia. Dermatol Ther. 2014;27(4):252–254. doi: 10.1111/dth.12130 [PubMed] [CrossRef] [Google Scholar]
41. Goren A, Shapiro J, Roberts J, et al. Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Dermatol Ther. 2015;28(1):13–16. doi: 10.1111/dth.12164 [PubMed] [CrossRef] [Google Scholar]
42. Goren A, McCoy J, Kovacevic M, et al. The effect of topical minoxidil treatment on follicular sulfotransferase enzymatic activity. J Biol Regul Homeost Agents. 2018;32(4):937–940. [PubMed] [Google Scholar]
43. McCoy J, Goren A, Kovacevic M, Shapiro J. Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil. J Biol Regul Homeost Agents. 2016;30(4):1153–1155. [PubMed] [Google Scholar]
44. Goren A, Castano JA, McCoy J, Bermudez F, Lotti T. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatol Ther. 2014;27(3):171–173. doi: 10.1111/dth.12111 [PubMed] [CrossRef] [Google Scholar]
45. Godin B, Touitou E. Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models. Adv Drug Deliv Rev. 2007;59(11):1152–1161. doi: 10.1016/j.addr.2007.07.004 [PubMed] [CrossRef] [Google Scholar]
46. Dias PCR, Miot HA, Trueb RM, Ramos PM. Use of minoxidil sulfate versus minoxidil base in androgenetic alopecia treatment: friend or foe?
Skin Appendage Disord. 2018;4(4):349–350. doi: 10.1159/000488011 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
47. Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104–109. doi: 10.1111/ijd.13838 [PubMed] [CrossRef] [Google Scholar]
48. Sriphojanart T, Khunkhet S, Suchonwanit P. A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata. Dermatol Rep. 2017;9(2):7399. doi: 10.4081/dr.2017.7399 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
49. Triyangkulsri K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Devel Ther. 2018;12:2323–2335. doi: 10.2147/DDDT.S172638 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
50. Gupta AK, Carviel J, Abramovits W. Treating alopecia areata: current practices versus new directions. Am J Clin Dermatol. 2017;18(1):67–75. doi: 10.1007/s40257-016-0230-4 [PubMed] [CrossRef] [Google Scholar]
51. Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15–24. doi: 10.1016/j.jaad.2017.04.1142 [PubMed] [CrossRef] [Google Scholar]
52. Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol. 1987;16(3 Pt 2):730–736. doi: 10.1016/s0190-9622(87)70095-4 [PubMed] [CrossRef] [Google Scholar]
53. Price VH. Topical minoxidil (3%) in extensive alopecia areata, including long-term efficacy. J Am Acad Dermatol. 1987;16(3 Pt 2):737–744. doi: 10.1016/s0190-9622(87)70096-6 [PubMed] [CrossRef] [Google Scholar]
54. Fiedler-Weiss VC. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J Am Acad Dermatol. 1987;16(3 Pt 2):745–748. doi: 10.1016/s0190-9622(87)80003-8 [PubMed] [CrossRef] [Google Scholar]
55. Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol. 1992;128(11):1467–1473. [PubMed] [Google Scholar]
56. Weiss VC, West DP. Topical minoxidil therapy and hair regrowth. Arch Dermatol. 1985;121(2):191–192. [PubMed] [Google Scholar]
57. Fiedler VC, Buys CM. Immunohistochemical characterization of the cellular infiltrate in severe alopecia areata before and after minoxidil treatment. Dermatologica. 1987;175 Suppl 2:29–35. [PubMed] [Google Scholar]
58. Ranchoff RE, Bergfeld WF, Steck WD, Subichin SJ. Extensive alopecia areata. Results of treatment with 3% topical minoxidil. Cleve Clin J Med. 1989;56(2):149–154. [PubMed] [Google Scholar]
59. Khoury EL, Price VH, Abdel-Salam MM, Stern M, Greenspan JS. Topical minoxidil in alopecia areata: no effect on the perifollicular lymphoid infiltration. J Invest Dermatol. 1992;99(1):40–47. doi: 10.1111/1523-1747.ep12611409 [PubMed] [CrossRef] [Google Scholar]
60. Fiedler-Weiss VC, Rumsfield J, Buys CM, West DP, Wendrow A. Evaluation of oral minoxidil in the treatment of alopecia areata. Arch Dermatol. 1987;123(11):1488–1490. [PubMed] [Google Scholar]
61. Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol. 2002;27(5):385–389. [PubMed] [Google Scholar]
62. Perera E, Sinclair R. Treatment of chronic telogen effluvium with oral minoxidil: a retrospective study. F1000Res. 2017;6:1650. doi: 10.12688/f1000research.10493.2 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
63. Harnchoowong S, Suchonwanit P. PPAR-gamma agonists and their role in primary cicatricial alopecia. PPAR Res. 2017;2017:2501248. doi: 10.1155/2017/2501248 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
64. Suchonwanit P, Hector CE, Bin Saif GA, McMichael AJ. Factors affecting the severity of central centrifugal cicatricial alopecia. Int J Dermatol. 2016;55(6):e338–e343. [PubMed] [Google Scholar]
65. Eginli A, Dothard E, Bagayoko CW, Huang K, Daniel A, McMichael AJ. A retrospective review of treatment results for patients with central centrifugal cicatrical alopecia. J Drugs Dermatol. 2017;16(4):317–320. [PubMed] [Google Scholar]
66. Fertig R, Tosti A. Frontal fibrosing alopecia treatment options. Intractable Rare Dis Res. 2016;5(4):314–315. [PMC free article] [PubMed] [Google Scholar]
67. Tosti A, Piraccini BM, Iorizzo M, Misciali C. Frontal fibrosing alopecia in postmenopausal women. J Am Acad Dermatol. 2005;52(1):55–60. [PubMed] [Google Scholar]
68. Khumalo NP, Ngwanya RM. Traction alopecia: 2% topical minoxidil shows promise. Report of two cases. J Eur Acad Dermatol Venereol. 2007;21(3):433–434. [PubMed] [Google Scholar]
69. Suchonwanit P, McMichael AJ. Alopecia in association with malignancy: a review. Am J Clin Dermatol. 2018;19(6):853–865. [PubMed] [Google Scholar]
70. Duvic M, Lemak NA, Valero V, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996;35(1):74–78. [PubMed] [Google Scholar]
71. Granai CO, Frederickson H, Gajewski W, Goodman A, Goldstein A, Baden H. The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies. Eur J Gynaecol Oncol. 1991;12(2):129–132. [PubMed] [Google Scholar]
72. Rodriguez R, Machiavelli M, Leone B, et al. Minoxidil (Mx) as a prophylaxis of doxorubicin–induced alopecia. Ann Oncol. 1994;5(8):769–770. [PubMed] [Google Scholar]
73. Prevezas C, Matard B, Pinquier L, Reygagne P. Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br J Dermatol. 2009;160(4):883–885. [PubMed] [Google Scholar]
74. Yang X, Thai KE. Treatment of permanent chemotherapy-induced alopecia with low dose oral minoxidil. Australas J Dermatol. 2016;57(4):e130–e132. [PubMed] [Google Scholar]
75. Djabali K, Panteleyev AA, Lalin T, et al. Recurrent missense mutations in the hair keratin gene hHb6 in monilethrix. Clin Exp Dermatol. 2003;28(2):206–210. [PubMed] [Google Scholar]
76. Rossi A, Iorio A, Scali E, et al. Monilethrix treated with minoxidil. Int J Immunopathol Pharmacol. 2011;24(1):239–242. [PubMed] [Google Scholar]
77. Chandran NS, Oranje AP. Minoxidil 5% solution for topical treatment of loose anagen hair syndrome. Pediatr Dermatol. 2014;31(3):389–390. [PubMed] [Google Scholar]
78. Sinclair R. Treatment of monilethrix with oral minoxidil. JAAD Case Rep. 2016;2(3):212–215. [PMC free article] [PubMed] [Google Scholar]
79. Cranwell WC, Sinclair R. Loose anagen hair syndrome: treatment with systemic minoxidil characterised by marked hair colour change. Australas J Dermatol. 2018;59(4):e286–e287. [PubMed] [Google Scholar]
80. Chanasumon N, Sriphojanart T, Suchonwanit P. Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis. Drug Des Devel Ther. 2018;12:365–372. [PMC free article] [PubMed] [Google Scholar]
81. Suchonwanit P, Chanasumon N, Sriphojanart T. Efficacy and safety of bimatoprost 0.01% for the treatment of eyebrow hypotrichosis: a randomized, double-blind, vehicle-controlled study. Dermatol Surg. 2019. doi: 10.1097/DSS.0000000000001944 [PubMed] [CrossRef] [Google Scholar]
82. Lee S, Tanglertsampan C, Tanchotikul M, Worapunpong N. Minoxidil 2% lotion for eyebrow enhancement: a randomized, double-blind, placebo-controlled, spilt-face comparative study. J Dermatol. 2014;41(2):149–152. [PubMed] [Google Scholar]
83. Worapunpong N, Tanglertsampan C. Treatment of eyebrow hypotrichosis with 1% minoxidil lotion: a prospective, randomized, double-blind, placebo-controlled trial. J Med Assoc Thai. 2017;100(5):574–577. [Google Scholar]
84. Suwanchatchai W, Tanglertsampan C, Pengsalae N, Makornwattana M. Efficacy and safety of bimatoprost 0.03% versus minoxidil 3% in enhancement of eyebrows: a randomized, double-blind, split-face comparative study. J Dermatol. 2012;39(10):865–866. [PubMed] [Google Scholar]
85. Ingprasert S, Tanglertsampan C, Tangphianphan N, Reanmanee C. Efficacy and safety of minoxidil 3% lotion for beard enhancement: a randomized, double-masked, placebo-controlled study. J Dermatol. 2016;43(8):968–969. [PubMed] [Google Scholar]
86. Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. J Am Acad Dermatol. 2002;46(2):309–312. [PubMed] [Google Scholar]
87. Dawber RP, Rundegren J. Hypertrichosis in females applying minoxidil topical solution and in normal controls. J Eur Acad Dermatol Venereol. 2003;17(3):271–275. [PubMed] [Google Scholar]
88. Peluso AM, Misciali C, Vincenzi C, Tosti A. Diffuse hypertrichosis during treatment with 5% topical minoxidil. Br J Dermatol. 1997;136(1):118–120. [PubMed] [Google Scholar]
89. Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008;59(4):547–566; quiz 567–548. [PubMed] [Google Scholar]
90. Earhart RN, Ball J, Nuss DD, Aeling JL. Minoxidil-induced hypertrichosis: treatment with calcium thioglycolate depilatory. South Med J. 1977;70(4):442–443. [PubMed] [Google Scholar]
Minoxidil Topical: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing
Minoxidil solution and foam are used to help hair growth in the treatment of male pattern baldness. It is not used for baldness at the front of the scalp or receding hairline in men. The foam and 2 percent minoxidil solution is also used to help hair growth in women with thinning hair.Minoxidil belongs to a class of drugs known as vasodilators. It is not known how minoxidil causes hair growth. This medication is not used for sudden/patchy hair loss, unexplained hair loss (for example, if you have no family history of hair loss), or hair loss after giving birth.Do not use this product if you are 18 years old or younger.
How to use Minoxidil Solution, Non-
Read and follow all directions on the product package before using this product. If you have any questions, ask your doctor or pharmacist.
Clean and dry the scalp area before applying the medication. You may apply this product to damp hair. To use the solution, fill the applicator with 1 milliliter of medication (to the 1 milliliter line), or use 20 drops. Part your hair in the area of thinning and apply the solution evenly to the affected area of the scalp. Gently rub in. Allow the solution to dry completely before using other styling products (such as gels, mousse) or before going to bed.
To use the foam, rinse your hands in cold water and dry well. Apply about 1/2 capful of foam to the scalp and rub in gently. Allow the foam to dry completely before styling or going to bed.
If scalp irritation is a problem, you may need to avoid using minoxidil on the same days that you have your hair colored or chemically treated (for example, permed).
Do not use on other parts of the body unless directed by your doctor. Do not use on skin that is red, painful, irritated, scraped, cut, or infected. Wash hands thoroughly after application. Avoid getting the medication in your eyes. If this occurs, rinse your eyes with large amounts of cool water.
Do not use this medication more often, apply more of it than as directed, or apply it to an irritated or sunburned scalp. Doing so can cause the drug to be absorbed into your body and result in serious side effects. This product may contain alcohol and can be irritating and drying to the scalp. Ask your doctor or pharmacist how to use this product safely.
It takes time for hair to regrow. Most people need to use this medication regularly for 4 months to see benefit. This medication must be used continuously to maintain hair growth. If your condition does not improve or worsens after using this medication for 4 to 6 months, or if you think you may have a serious medical problem, tell your doctor.
Burning, stinging, or redness at the application site may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.
If your doctor has directed you to use this medication, remember that your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Rarely, this medication can be absorbed through the skin and cause side effects. Stop using this medication and tell your doctor right away if you have any serious side effects, including: unwanted facial/body hair, dizziness, fast/irregular heartbeat, fainting, chest pain, swelling of hands/feet, unusual weight gain, tiredness, difficulty breathing especially when lying down.
A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
In the US – Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.
In Canada – Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Before using minoxidil, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.
If you have any of the following health problems, consult your doctor or pharmacist before using this product: diseases of the scalp (such as eczema, infection, cuts), heart problems (such as chest pain, heart attack, heart failure), kidney disease, liver disease.
During pregnancy, this product should be used only when clearly needed. Discuss the risks and benefits with your doctor.
It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.
Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor’s approval.
Some products that may interact with this drug include: drugs for high blood pressure (such as guanethidine), drugs that interact with alcohol (such as disulfiram, metronidazole).
Does Minoxidil Solution, Non- interact with other drugs you are taking?
Enter your medication into the WebMD interaction checker
This medicine may be harmful if swallowed. If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: dizziness, drowsiness, fainting, flushing.
Keep all medical and lab appointments.
If you miss a dose, skip the missed dose. Use your next dose at the regular time. Do not double the dose to catch up.
Store at room temperature away from heat. This product is flammable. Keep it away from fire, and avoid open flame after treatment until the medication has completely dried. Keep all medications away from children and pets.
Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Save up to 80% on your prescriptions.
Save up to 80% on your prescription with WebMDRx
Have you ever purchased Minoxidil Solution, Non-?
Yes, In the past 3 months
Yes, In the past 6 months
Yes, In the past year
Haven’t purchased but considering
Don’t plan to purchase
This survey is being conducted by the WebMD marketing sciences department.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.
Minoxidil for hair, the benefits and harms of minoxidil
Androgenetic alopecia most often develops in the stronger sex and leads to male pattern hair loss. This is due to the peculiarities of the hormonal background, in which the endocrine system produces an excessive amount of the male sex hormone – dihydrotesterone, which negatively affects the quality of the hair, causing hair loss, thinning and growth retardation.
It is worth noting that Minoxidil is mainly suitable for men. For the fair sex, androgenic baldness is very rare, in exceptional cases. And as an option, you can use 2% Minoxedil. A big plus of the drug is the absence of smell.
Supplied as a spray or foam. Active ingredient concentration: 2–15%. The drug is suitable for any form of hair, even for the most complex hairstyles.
The most popular minoxidil brands on the market are Rogaine and Alerana.
Rogaine consists of minoxidil, purified water and a combination of citric and lactic acids. Other components include stearic alcohol and glycerol. Alerana, in addition to the usual minoxidil and purified water, contains ethyl alcohol and propylene glycol.
There are situations when there is an allergic reaction to one of the components of the drug. Then, for the treatment of hair loss, the doctor may prescribe other drugs with a similar effect. Active analogues of minoxidil are preparations based on nanoxidil (Spectral DNS), aminexil (Vichy Dercos) and stemoxidine (Vichy Dercos Neogens).
To enhance the effect, in addition to taking medications, the doctor may recommend taking vitamins and microelements, the composition of which is selected specifically for hair, and not for general action. Also a good recommendation is mesotherapy and PRP/Price
The cost of the drug directly depends on the percentage of minoxidil in its composition. The most popular solutions are those containing 2% and 15% minoxidil. Accordingly, the first option will cost $13–15, while a five percent solution will cost $18–50.
The drug belongs to the conditional category “cost above average”, and due to the active appreciation of the dollar against the Russian ruble in recent days, its purchase may feel even more expensive. However, the price of the drug is fully justified, since minoxidil is one of the most effective substances for the treatment of hair loss, regardless of whether it is caused by a genetic predisposition or is one of the post-covid syndromes.
Instructions for use
It is best not to use Minoxidil as soon as a problem of hair loss is discovered, but to consult a trichologist. And especially not to use every day. Alcohol-containing solution often leads to flaking of the scalp. The maximum safe frequency is every other day for the night!
The daily dose of the drug – 1 ml of solution – is equal to seven injections on the scalp. In general, it is determined by the attending physician, but these are standard values. If the drug is supplied in the form of a foam, then 1 ml of the solution is approximately equal to half the vial cap.
Use of the product is as follows:
- First, the scalp is cleaned.
- The preparation is then gently rubbed into the skin.
- Leave on for several hours, the main thing is not to wash it off.
Regular use of the drug is implied, short-term use will not give the desired effect.
- allergic to minoxidil and other components of the drug;
- skin lesions of the head;
- diseases of the cardiovascular system, liver, kidneys;
- Minoxidil is likely to be incompatible with other hair loss medications, we strongly recommend that you consult your doctor about additional contraindications.
Rare but should be known in advance:
- burning eyes;
- allergy in the form of itching and rash;
- swelling of the tongue, lips and throat;
- lowering blood pressure;
- palpitations; dyspnea.
Why is Minoxidil dangerous?
The appearance of side effects is possible both on the part of the hair and the body as a whole. Minoxidil is a crystalline powder that is dissolved in alcohol, which is quite drying to the skin and can cause seborrhea, dryness, tightness, and flaking. Harm from the use of Minoxidil can also be manifested from the side of the cardiovascular system – such manifestations as dizziness, tachycardia and chest pain are possible. An allergic reaction is also possible.
Action of minoxidil against baldness, against hair loss and for hair growth
You are here
Learn more about how Rogaine
® Foam with Minoxidil 5% works.
Foam Regaine contains a 5% solution of minoxidil 1 , which is considered the first line drug in the treatment of hereditary baldness – androgenetic alopecia 7 . Exactly how minoxidil works when applied topically is not completely known. According to the instructions for medical use of the drug, minoxidil in the foam Regaine ®1 :
- dilates the blood vessels of the scalp and improves blood flow around the hair follicles;
- promotes the formation of vascular endothelial growth factor, a substance that is believed to increase the permeability of small vessels, which indicates a high metabolic activity in anagen – the phase of active hair growth.
Rogaine Foam ® , indicated for the treatment of androgenetic alopecia 1 , is clinically proven 2,3,4 . Nine out of ten men 4 and 81.5% of women 5 note that with regular external use of minoxidil, hair loss stops within two months, and new ones appear in place of vellus and previously lost hair 4.5 . The best effect of the drug is noted at the initial stage of the disease and with moderate androgenetic alopecia 1 .
How to use Regaine®
The drug is approved for use from 18 years of age and has contraindications 1 – it is important to consider them. Therefore, before using Regaine ® , read the instructions for its medical use and consult a specialist. How to use Rogaine®? 1
- Apply Rogaine ® Foam with clean, dry hands to dry scalp, not hair. This can increase the effectiveness of the drug, as it will be easier to reach the hair follicles.
- Since the foam may dissolve on contact with warm skin, rinse your fingers with cold water and dry them before squeezing it out.
- Spread the foam evenly over the areas of baldness and use your fingertips to gently rub it into the skin.
Men are recommended to perform the procedure twice a day (morning and evening), women – once a day. If you use the product more often, this will not affect the result of treatment 1 .
Within 4 hours after application of Rogaine ® Do not wash or blow dry your hair. You can comb during treatment as usual. However, before styling, you must wait until the foam is completely dry, and then use styling products 1 .